Physician profile

Kenneth Robert Murray

Neurology (Psychiatry & Neurology) · Cullman, AL

NPI 1265594733

$2,518.97

in general payments reported to CMS, 2019-2025

33 companies · $961 in 2025

The $961 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

See the full distribution for Neurology (Psychiatry & Neurology)

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$2,028.27
Education$13.40

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Jazz Pharmaceuticals INC. $318.30 2019-2025
Axsome Therapeutics, INC. $290.33 2023-2025 Sunosi, Symbravo
Eisai INC. $248.31 2019-2025
Lilly USA, LLC $220.25 2023-2025 Kisunla, Amyvid, Zepbound
Neurocrine Biosciences, INC. $153.59 2024-2025 Ingrezza
Abbvie INC. $146.40 2023-2025
Harmony Biosciences LLC $120.56 2023-2024 Wakix
Ge Healthcare $104.67 2019-2021
Livanova USA, INC. $94.44 2019
Neurelis, INC. $85.75 2023-2025 Valtoco
Acadia Pharmaceuticals INC $77.87 2025 Nuplazid
Baxter Healthcare $73.04 2024-2025 Hillrom - Vest System Model 105 Home Care
Biogen, INC. $61.01 2024-2025 Leqembi
Philips North America LLC $55.04 2024-2025 Reusable Vest, Vest Therapy Und, (Ak6) Vest Therapy
Ucb, INC. $37.93 2019
Show all 33 companies
CompanyGeneral paymentsYearsTop products
Grifols USA, LLC $35.26 2019-2024 Prolastin-C Liquid
Genzyme Corporation $32.48 2024
Pfizer INC. $32.31 2025
Astrazeneca Pharmaceuticals LP $32.10 2024-2025 Airsupra
Mylan Specialty L.P. $31.91 2024 Yupelri
Takeda Pharmaceuticals U.S.A., INC. $31.51 2025 Glassia
Csl Behring $27.87 2025 Hizentra
Amgen INC. $24.54 2024 Uplizna
Acorda Therapeutics, INC $23.65 2019
Tanabe Pharma America, INC. $23.65 2025 Radicava
Novartis Pharmaceuticals Corporation $22.19 2019
Paratek Pharmaceuticals, INC. $19.46 2023 Nuzyra
Kyowa Kirin, INC. $19.12 2023 Nourianz
Avadel Cns Pharmaceuticals, LLC $17.69 2024 Lumryz
Teva Pharmaceuticals USA, INC. $16.58 2025 Austedo Xr
Amneal Pharmaceuticals LLC $15.22 2023 Rytary
Ceribell, INC. $13.18 2024 Pocket Eeg Device
Arbor Pharmaceuticals, INC. $12.76 2019-2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$2,000.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Kenneth Robert Murray

$2,518.97

in general payments reported 2019-2025

Years
2019-2025
Top company
Arbor Pharmaceuticals, INC.
Context
The $961 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).

https://glasscript.com/doctor/330190/kenneth-robert-murray

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.